Indivior Dividends - INDV

Indivior Dividends - INDV

Buy
Sell
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type
Indivior Plc INDV London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
9.40 3.1% 312.60 16:35:26
Open Price Low Price High Price Close Price Previous Close
308.20 306.60 312.80 312.60 303.20
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Indivior INDV Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
18/02/2016FinalUSX9.531/12/201431/12/201516/06/201617/06/201629/07/201612.7
05/08/2015InterimUSX3.230/12/201430/06/201517/09/201518/09/201523/10/20150

Top Dividend Posts

DateSubject
23/6/2022
12:12
gibbs1: INDIVIOR PLC (INDV) Real-time Estimate Cboe Europe - 07:11 2022-06-23 am EDT 300.20 GBX +2.81%
09/6/2022
11:07
casholaa: Dunno, the PI is always the last to know anything worth knowing. But, I am pleased that INDV will have the opportunity to take more shares out of circulation at a lower cost. Today we have the ECB interest rates and the US weekly jobless rates. The Markets work in mysterious ways.
01/6/2022
15:04
timmy11: Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder 01/06/2022 2:50pm PR Newswire (US) Indivior (LSE:INDV) Intraday Stock Chart Wednesday 1 June 2022 Click Here for more Indivior Charts. SLOUGH, England and RICHMOND, Va., June 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma announced a strategic collaboration that includes an exclusive option and license agreement for the global rights to AEF0117, a first-in-class synthetic Signaling Specific Inhibitor ("SSI") engineered to inhibit the cannabinoid type 1 ("CB1") receptor ("CB1-SSI").
27/5/2022
11:06
waldron: Indivior to Participate in Jefferies 2022 Healthcare Conference Slough, UK and Richmond, VA - May 24, 2022 - Indivior PLC (LON: INDV) today announced that Mark Crossley, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will participate in the Jefferies 2022 Healthcare Conference in New York City. Mark Crossley will present on June 8, 2022, at 8:00 AM (US ET). The live presentation will be available on Indivior's website www.indivior.com and can also be viewed using the following webcast link: Https://wsw.com/webcast/jeff240/indv.l/2067675 . About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
03/5/2022
09:49
waldron: 3 May 2022 Indivior Announces Share Repurchase Program Details Slough, UK and Richmond, VA, 3 May, 2022 - Indivior PLC (LON: INDV) today announced that, as outlined in its Q1 results on 28 April 2022, it will commence a share repurchase program of Indivior's ordinary shares (the "Ordinary Shares") for up to a maximum consideration of $100 million (the "Program"). Indivior PLC ("Indivior") announces that it has entered into a non-discretionary agreement with Stifel Nicolaus Europe Limited ("Stifel") in relation to the Program and for Stifel to carry out on-market purchases, acting as riskless principal, during the period commencing on 3 May, 2022 and ending no later than 31 March, 2023, of the Ordinary Shares and the simultaneous on-sale of such Ordinary Shares by Stifel to Indivior.
29/4/2022
16:56
waldron: [United Kingdom] INDIVIOR PLC (INDV) 313.60 GBX -5.14%
28/4/2022
08:36
youngers: Another strong quarter with growth momentum holding or even increasing in the all important sublocade. My only criticism is they again released at wrong time. They said midday. Slough, UK, and Richmond, VA, April 7, 2022 - Indivior PLC (LON: INDV) today announced that it will release its Q1 2022 results on April 28(th) at 12:00 GMT (7:00 a.m. U.S. Eastern).
08/4/2022
12:27
the grumpy old men: Indivior to Announce Q1 2022 Results and Host Webcast on April 28(th) Slough, UK, and Richmond, VA, April 7, 2022 - Indivior PLC (LON: INDV) today announced that it will release its Q1 2022 results on April 28(th) at 12:00 GMT (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com . Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on April 28(th) . Access to the Live Webcast Presentation The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. The webcast link is hxxps://edge.media-server.com/mmc/p/ogy6nn93 . Participants may access the presentation telephonically : -- US participants 1-646-741-3167 -- International participants +44 (0) 2071-928338 Please reference confirmation ID 6687840. A replay of the presentation will be available at www.indivior.com . About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
04/4/2022
09:23
florenceorbis: 31 March 2022 Indivior to Commence Formal Shareholder Consultations on Additional US Listing Richmond, VA, March 31, 2022 - Indivior PLC, (LON: INDV) today announced that further to its announcement on February 16, 2022, it is commencing formal consultations with shareholders on the potential for an additional listing of Indivior shares in the US on a major stock exchange. The Board believes that an additional US listing is likely to be beneficial to elevating the Group's profile in its largest market. In coming to its view, the Board considered the following key elements of the Group's strategy, structure and opportunity: -- Approximately 80% of Group's net revenue is generated in the US; -- The US currently is, and is expected to remain, the Group's largest and highest value market for its key treatments (SUBLOCADE (R) and PERSERIS (R) ); -- Healthcare comprises approximately 20% of US gross domestic product (GDP) and, as such, the US contains the largest pool of biopharma-focused investors and research analyst coverage; -- The CEO and a majority of the Group's leadership team are based in the US; -- 40%-plus of shareholders are based in North America; and -- Provides a US stock currency for potential business development. The Board looks forward to receiving investor feedback during the consultations and, if supportive, the Board intends to put forward a formal shareholder resolution in September of this year that would facilitate an additional listing in the US. Comment by Graham Hetherington, Chair of the Board In assessing Indivior's optimal listing structure, the Board's approach is always to consider what is in the best interests of the Group and all of its stakeholders over the long-term. The Board believes that an additional US listing in the near-term would be beneficial because we believe it will raise the Group's profile in its highest value market and potentially attract a broader group of biopharma shareholders. Longer-term, it also provides the Group with the optionality to pursue a primary or sole US listing, if appropriate. We have received initial positive feedback from a broad range of shareholders on the potential of an additional US listing. We are, however, mindful that this is a complex issue for shareholders, and we look forward to commencing a period of formal consultations with our shareholders. We will listen carefully to all shareholder feedback and expect to make a further announcement following the conclusion of shareholder consultations, which is likely to be in July of this year in conjunction with the Group's H1 2022 results. Background In conjunction with its FY 2021 results release on February 16, 2022, the Group's Board indicated that it had been assessing the optimal listing structure for Indivior shares and that its preliminary view was that an additional listing of Indivior shares on a major US stock exchange is likely to be beneficial to the Group's profile and ability to attract a broader group of biopharma-focused investors and research analysts. The Board is now formally commencing further consultations with institutional shareholders on the potential of such an additional US listing. More detail on the US additional listing considerations can be found in the Consultation presentation on the Group's website. If supported by shareholders, the key considerations and anticipated timings for an additional US listing are as follows: -- Additional listing of Indivior shares on a major US stock exchange (i.e., NASDAQ, NYSE); -- Full premium London Stock Exchange listing maintained; -- FTSE indexation maintained; -- Requires shareholder approval by a majority of 75% (of votes cast) of a resolution to amend Indivior's articles of association to facilitate settlement of its shares in the UK and US; -- Extraordinary General Meeting of shareholders to obtain such approval in September 2022; and -- Earliest implementation of additional US listing in Spring 2023.
13/10/2021
09:12
ariane: Indivior : to Announce Q3 / 9 Months YTD 2021 Results and Host a Presentation on October 28th 10/12/2021 | 02:42pm BST Indivior to Announce Q3 / 9 Months YTD 2021 Results and Host a Presentation on October 28th 12/10/2021 Slough, UK, and Richmond, VA, October 12, 2021 - Indivior PLC (LON: INDV) today announced that it will release its Q3 / 9 months YTD 2021 results on October 28th at 12:00 London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com. Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a conference call presentation via a live webcast at 13:00 London time (8:00 a.m. U.S. Eastern) on October 28th. Access to the Live Webcast Presentation The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. The webcast link is: hxxps://edge.media-server.com/mmc/p/oy28w6i3. Participants may access the presentation telephonically: US participants 1-646-741-3167 International participants +44 (0) 2071-928338 Please reference confirmation ID 6677702. A replay of the presentation will be available at www.indivior.com. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.comto learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
ADVFN Advertorial
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220625 20:36:31